Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NK Cells (CCT-ANK-11) in Solid Tumors
NCT06284226Phase 1Withdrawn
- Sponsor
- Beijing Kejing Biotechnology
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of CCT-ANK-11 in pancreatic cancer (PC), esophageal cancer, gastric cancer (GC) and 3 more, sponsored by Beijing Kejing Biotechnology. Primary endpoints: Safety Evaluation at 12 months and Efficacy Evaluation at 12 months. Planned start Mar 2022; status: withdrawn.
02
Drugs
CCT-ANK-11
03
Conditions
pancreatic cancer (PC)esophageal cancergastric cancer (GC)cholangiocarcinoma (CCA)lung cancer
Beyond the preview
Go deeper on NCT06284226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284226.